Web Exclusives

A new laboratory-based scoring system may allow physicians to better predict which patients with early-stage CLL are most likely to require early treatment.

Patients with CLL may be at increased risk for developing severe COVID-19. Experts have provided insights on how to protect them while still delivering optimal care.

Updated National Comprehensive Cancer Network (NCCN) guidelines now recommend zanubrutinib as alternative first- and second-line therapy for some patients.

Cannabis compounds such as cannabidiol have shown cancer-fighting activity in the lab. What should patients know?

April is National Minority Health Month and National Minority Cancer Awareness Month, a time to reflect and shine a light on the disparities that minority populations face in cancer care.

A new model of the symptoms and impacts faced by patients may lead to better clinical tools for understanding the patient experience.

Patients who are in a period of active observation should feel comfortable sharing anything that seems abnormal with their healthcare provider.

A greater number of comorbidities alone may not be sufficient to predict patient survival; age and stage at diagnosis must be considered as well.

The first phase 3 trial comparing these drugs shows that acalabrutinib has similar efficacy as ibrutinib with a lower risk of a worrisome side effect.